Zhao Fei, Ji Zheng, Chi Jufang, Tang Weiliang, Zhai Xiaoya, Meng Liping, Guo Hangyuan
Acta Cardiol. 2016 Feb;71(1):27-34. doi: 10.2143/AC.71.1.3132094.
The objective of this study was to determine similarities in the effect of yellow wine as compared to statin and the possibility that yellow wine inhibits tumour necrosis factor-α (TNF-α)-induced nitric oxide (NO) synthesis, endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and intercellular adhesion molecule-1 (ICAM-1) in cultured rat vascular endothelial cells (VECs).
We isolated VECs, and cultivated and purified Sprague Dawley (SD) rat thoracic aortas in vitro. We selected the optimal wine concentration using clonogenic and MTT assays to measure cell survival. Next, we divided the cells into 9 groups: (1) control, (2) TNF-α, (3) TNF-α + rosuvastatin (10 μmol/L), (4) TNF-α + ethanol 0.5%, (5) TNF-α + yellow wine 0.5%, (6) TNF-α + ethanol 1.0%, (7) TNF-α + yellow wine 1.0%, (8) TNF-α + ethanol 1.5%, and (9) TNF-α + yellow wine 1.5% and they were given the corresponding treatment for 24 h. We determined NO production with nitrate reductase. We then measured eNOS activity, and detected eNOS, iNOS, and ICAM-1 protein levels by Western blotting.
Compared with the TNF-α group, NO production, eNOS activity, and eNOS protein expression in the rosuvastatin, and yellow wine 1.0%, and 1.5% groups were significantly increased. Protein expression of iNOS and ICAM-1 in the rosuvastatin, yellow wine 1.0%, and 1.5% groups were significantly decreased. Compared with the rosuvastatin group, eNOS, iNOS, and ICAM-1 protein expression in the yellow wine (0.5% -1.5%) groups were significantly different.
Treatment with yellow wine increased NO production, eNOS activity, and eNOS protein expression, which decreases iNOS and ICAM-1 protein expression. We conclude that yellow wine may have similar beneficial effects as rosuvastatin on the cardiovascular system. These effects may be attributed to their anti-atherosclerotic actions.
本研究的目的是确定黄酒与他汀类药物在作用方面的相似性,以及黄酒抑制肿瘤坏死因子-α(TNF-α)诱导的培养大鼠血管内皮细胞(VECs)中一氧化氮(NO)合成、内皮型一氧化氮合酶(eNOS)、诱导型一氧化氮合酶(iNOS)和细胞间黏附分子-1(ICAM-1)的可能性。
我们分离了VECs,并在体外培养和纯化了Sprague Dawley(SD)大鼠胸主动脉。我们使用克隆形成和MTT试验选择最佳葡萄酒浓度以测量细胞存活率。接下来,我们将细胞分为9组:(1)对照组,(2)TNF-α组,(3)TNF-α+瑞舒伐他汀(10μmol/L)组,(4)TNF-α+0.5%乙醇组,(5)TNF-α+0.5%黄酒组,(6)TNF-α+1.0%乙醇组,(7)TNF-α+1.0%黄酒组,(8)TNF-α+1.5%乙醇组,和(9)TNF-α+1.5%黄酒组,并给予相应处理24小时。我们用硝酸还原酶测定NO生成量。然后我们测量eNOS活性,并通过蛋白质印迹法检测eNOS、iNOS和ICAM-1蛋白水平。
与TNF-α组相比,瑞舒伐他汀组、1.0%和1.5%黄酒组的NO生成量、eNOS活性和eNOS蛋白表达均显著增加。瑞舒伐他汀组、1.0%和1.5%黄酒组中iNOS和ICAM-1的蛋白表达均显著降低。与瑞舒伐他汀组相比,黄酒(0.5%-1.5%)组中eNOS、iNOS和ICAM-1的蛋白表达有显著差异。
黄酒处理可增加NO生成量、eNOS活性和eNOS蛋白表达,降低iNOS和ICAM-1蛋白表达。我们得出结论,黄酒在心血管系统方面可能具有与瑞舒伐他汀相似的有益作用。这些作用可能归因于它们的抗动脉粥样硬化作用。